Italian radiopharmaceutical firm Bracco last month signed an agreement with Caffaro, the lead company of Italian firm Snia Group’s Chemical and Energy sector. The agreement allows Bracco to build a new plant on the site of Industrie Chimiche Caffaro
Italian radiopharmaceutical firm Bracco last month signed an agreement with Caffaro, the lead company of Italian firm Snia Groups Chemical and Energy sector. The agreement allows Bracco to build a new plant on the site of Industrie Chimiche Caffaro in Torviscosa. The plant will manufacture Braccos imaging contrast media products, and Bracco will use the raw materials, utilities, facilities, and services already available at the site. The plant will eventually employ approximately 100 people.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment
June 2nd 2025Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.